N (%) | |
---|---|
ART | |
Components of ART regimena | |
NRTI backbone | |
TDF + 3TC or FTC | 160 (95.2) |
AZT + 3TC or FTC | 8 (4.8) |
EFV-based regimenb | 141 (83.9) |
NVP-based regimen | 3 (1.8) |
Lop/rit-based regimenc | 21 (12.5) |
Triple NRTI regimen using ABC | 3 (1.8) |
Number of days between diagnosis and initiation of ART, median (IQR) | 13.0 (6.0-26.5) |
ART started within ≤7 days of diagnosisd | |
Among all subjects | 42 (33.9) |
Among those with advanced disease | 29 (37.7) |
Co-trimoxazole | |
Among all subjectse | 83 (52.9) |
Among those with CD4 ≤350 cells/mm3 OR stage 3 or 4 diseasef | 77 (64.7) |
IPT | |
No TB symptoms presentg | 77 (46.4) |
Active extra-pulmonary TB | 4 (5.2) |
Eligible for IPT: No TB screening symptoms or active TB | 73 (44.0) |
INH prescription providedh | 1 (1.4) |
TB symptoms present | 89 (53.6) |
Diagnostic evaluation performed | 35 (39.3) |
Diagnostic evaluation negativei | 25 (71.4) |
Fluconazole | |
CD4 <100 and neurological symptoms present | 7 (5.3) |
CD4 <100 and no neurological symptoms presentj | 46 (34.6) |
CrAg screening | 0 (0) |
Fluconazole prescription provided | 0 (0) |